OncoCyte Corp (NASDAQ:OCX) announced Q3 2023 financial results with a net loss of $6.5 million.
Positive CMS coverage decision for VitaGraft Kidney test, with product launches expected in 1H 2024.
Reduced cash burn to $3.6 million in Q3, with $14.2 million in cash and equivalents on hand.
Revenue for Q3 stood at approximately $0.4 million, primarily from increased Pharma Services.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.